N 6022

Drug Profile

N 6022

Alternative Names: N6022

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NitroMed
  • Developer Nivalis Therapeutics
  • Class Amides; Anti-inflammatories; Antiasthmatics; Carboxylic acids; Pyrroles; Small molecules
  • Mechanism of Action Alcohol dehydrogenase inhibitors; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute asthma; Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases
  • Discontinued Cystic fibrosis

Most Recent Events

  • 25 Jul 2017 Alpine Immune Sciences has merged with Nivalis Therapeutics forming Alpine Immune Sciences
  • 31 May 2014 N30 Pharmaceuticals completes a phase Ib trial in Cystic fibrosis in USA (NCT01746784)
  • 20 Mar 2013 Preclinical pharmacodynamics data from a mouse model of asthma released by N30 Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top